Precision immune modulation for durable remission in autoimmune disease
Serendo Therapeutics is developing targeted therapies designed to address the underlying biology of autoimmune disease and help move treatment beyond chronic symptom control.
Preclinical program — no approved products.
Autoimmune diseases encompass a wide and complex range of chronic conditions that impact multiple organ systems, placing an increasing burden on patients, healthcare systems, and society worldwide. Despite significant advances in treatment, many patients still experience persistent disease activity, long-term complications, and the lasting effects of inadequate disease control. For numerous autoimmune disorders, a cure remains elusive. Consequently, there is a continuous global demand for therapies that provide deeper and more durable disease management.
The burden of incomplete disease control
For patients, not-well-managed disease can mean ongoing inflammation, pain, fatigue, reduced quality of life, and progressive complications over time. For health systems, it means continued treatment cycling, persistent burden, and unmet need despite available therapies.
A new approach to immune modulation
Serendo Therapeutics is advancing a differentiated therapeutic approach designed to modulate the intracellular pathways that sustain harmful immune activation. Our goal is not only to suppress symptoms, but to help reset disease-driving immune responses more precisely and more durably.
Built for diseases with high unmet need
We focus on underserved areas of autoimmune disease and patients with refractory conditions, where unmet medical need remains highest. Our program is anchored in clear biological rationale and supported by translational models, enabling efficient paths to early proof-of-concept and clinical validation.